Risk ratios (RR) for cardiovascular death estimates according to direct (DPP-4 inhibitors, GLP-1RA and SGLT-2 inhibitors against placebo) and indirect (DPP-4 inhibitors vs GLP-1RA or SGLT-2 inhibitors, and GLP-1RA vs SGLT-2 inhibitors) comparisons
To attain these health benefits, however, it is critical that people prescribed GLP-1s continue to take them at least long enough to realize clinical success, and preferably longer to avoid possible weight rebound once they come off the medications
Images are ai generated for viewing consistency
Bananas (unripe)
Noseparating them by 30 to 60 minutes or longer reduces the risk of tirzepatide slowing levothyroxine absorption
What the Brand Says About How These Medications May Work The brand's materials describe semaglutide as a medication that "may work through the GLP-1 pathway" and tirzepatide as one that "may work through both GIP and GLP-1 pathways." Per the official website, GLP-1-based treatment "may be considered as part of a broader provider-guided care plan for weight care," and the brand frames weight care generally as involving "a range of factors, including appetite signaling, metabolism, and overall health history" - not a single mechanism or a guaranteed outcome